Authorities 8 This opinion cites: Henderson v. However, the Arbitrator determined that both parties contemplated and anticipated that International Gene Group, Inc. He acted simultaneously for both parties to the License Agreement. GlycoGenesys, Inc. Platt's retention of control of the interference proceeding and the Application. See generally Everex Sys. This report will not be deemed an admission as to the materiality of any information in the report that is required to be disclosed solely by Regulation FD. The first poster will be presented by Dr. State Farm Fire and Cas.
Glycogenesys Inc 8K Current report
GlycoGenesys, Inc. (GLGS) Claims Rights To Davanat In Lawsuit With Platt And Pro-Pharmaceuticals, Inc.; Company's Rights To GCS Not In Dispute - read. GlycoGenesys, Inc. Claims Rights to Davanat in Lawsuit with Platt and Pro- Pharmaceuticals, Inc.; Company's Rights to GCS Not In Dispute.
In Re GlycoGenesys, Inc., B.R. –
Opinion for In Re GlycoGenesys, Inc., B.R. — Brought to you by Dr. David Platt and Pro-Pharmaceuticals, Inc. (collectively, "").
During the period from late toDr.
Video: Glycogenesys inc. and platt Glycogenesis - Glycogen Synthesis in Hindi
Platt will be cured by the payment of cure costs,  and that Dr. Platt's argument elevates form over substance and ignores the reality of how the Debtors operated. Much as GlycoGenesys has done through the arbitration process, we will pursue this legal action in a manner that minimizes management's time and is results driven. We rely on donations for our financial security.
David Platt wants to cure cancer. Can his company avoid life support The Boston Globe
VASTGESTELD BESTEMMINGSPLAN OPVRAGEN
David Platt the "License Agreement".
Regarding the Quarter Ended September 30, The equipment was not essential to the Debtors' development of its pharmaceutical products which were manufactured by a third party. The Company is seeking damages and permanent injunctive relief including: -- an order to assign all rights in Davanat and other Pro-Pharmaceutical's inventions to GlycoGenesys; -- a permanent injunction on Platt and Pro-Pharmaceuticals from developing, selling or using polysaccharide compounds to treat cancer; -- a permanent injunction on Platt and Pro-Pharmaceuticals from using proprietary and confidential information of GlycoGenesys; -- an injunction preventing Platt from participating in the business of Pro- Pharmaceuticals for 2 years; and -- the recovery of all payments made to Platt under the termination agreement as well as associated costs and attorneys fees GlycoGenesys, Inc.
The Court concludes that federal common law does not preclude the Trustee from assuming and assigning the License Agreement.
GlycoGenesys files counterclaim lawsuits Boston Business Journal
or Their Counterclaims Against Dr. Platt & Pro-Pharmaceuticals. GlycoGenesys, Inc. (together with its subsidiaries, as the context requires, the Dr.
GlycoGenesys, Inc. Believes Platt Lawsuit Is Without Merit Company
David Platt and Wayne State University and the Barbara Ann Karmanos.
David Platt, testified at the hearing and 17 exhibits were introduced into evidence. Cambridge Biotech Corp.
On May 31,the board of directors of SafeScience, Inc. Regardless of whether the Platt applications or Raz patent prevails or both are allowed as patents, we have exclusive licenses to both.
Cambridge Biotech Corporation, Exhibit